Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2016-2017. WHO. (2018)

immage

The aim of the report is to document participation efforts and outcomes across countries, and highlight differences and constraints identified to date. In this first GLASS report data vary considerably in terms of completeness, so no attempt was made to compare AMR status at a regional or global level. However, as GLASS and country participation evolves, the data reported will help understand surveillance capacities and mechanisms of reporting across countries in all regions, and will inform further GLASS development. 


Keywords: AMR, surveillance systems, infections, resistance

 

Download Publication

Progress Report on Access to Hepatitis C Treatment. WHO. (2018)

immage

This report updates the first edition, published in 2016, and reviews the progress countries have made in expanding access to life-saving DAAs. The report reviews the main challenges countries face and describes recent developments in relation to five key factors that determine access to DAA medicines: affordability, quality assurance, regulatory approval, government commitment and financing. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners. 


Keywords: HCV, treatment, medicines, response

 

Download Publication

FAQ - Price Reduction of the Dolutegravir-based Antiretroviral Therapy Regimen. UNAIDS. (2018)

immage

This is the first time this regimen will be offered as an affordable, generic, fixed-dose combination, which will increase access for millions of people living with HIV in low- and  middle-income countries. Below are a set of key messages and questions and answers  to guide communications around the announcement and respond to media inquiries.

 

 

Keywords: HIV, ART, treatment, medicines, funding

 

Download Publication

Drug Dependence Treatment in Thailand: Progress against Persistent Concerns. Tanguay P and Ngammee V. (2018)

immage

In 2016, the Kingdom of Thailand formally decided to re-allocate responsibility for drug dependence treatment from the Ministry of Justice (MOJ) to the Ministry of Public Health (MOPH) by the end of 2018. The reforms are designed to increase voluntary access to client-centred drug dependence treatment where the MOPH will be expected to develop guidelines, operating standards and monitoring and evaluation indicators to assess performance. Although Thailand’s drug treatment system has raised significant concerns over the past 15 years, this change is intended by the Government to indicate a shift in the overall approach to drug use and dependence to one based on health and human rights.


Keywords: law enforcement, human rights, harm reduction, drug
 

 

Download Publication

Briefing Paper: Drug Dependence Treatment in China: A Policy Analysis. Tibke P. (2017)

immage

Drug use and supply have been a sensitive and high-priority issue for successive governments in China since at least the Opium Wars in the mid-19th century. China’s policy response to drug use relies on punishment and coercion as central components, including compulsory detoxification, detention in labour camps or so-called ‘rehabilitation’ facilities, and compulsory registration with law enforcement authorities resulting in surveillance and random interrogations. 

 

Yet, in the late-1990s, in a policy move that appeared to emphasize healthcare instead of punishment for people who inject drugs, China began implementing the world’s largest scale-up provision of opioid substitution therapy (OST) and needle and syringe programmes (NSP) – two critical harm reduction measures for preventing HIV transmission. However, the overall approach towards people who use drugs remains punitive and stigmatising in China. As drug use continues to rise and expand across a greater range of drugs (especially synthetic drugs such as methamphetamine), as well as amongst younger age groups, China requires a comprehensive system of evidence-based and humane drug treatment and harm reduction services capable of advancing the health and quality of life of individuals and communities.

 

Keywords: China, HIV, PWID, NSPs and OST, drugs, health, law

 

Download Publication

Global Hepatitis Report, 2017. WHO. (2017)

immage

This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.

 

The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030. 


Keywords: HIV, HCV, HBV, prevention, testing, treatment

 


Download Global Hepatitis Report 2017

 

Download Executive Summary

 

Patients Helping Patients Understand Opioid Substitution Treatment. Chapman J, Fowler A, Mackenzie B, et al. (2017)

immage

This handbook has been written by a group of patients in British Columbia. We all have long experience with medication-assisted treatments for opioid dependence. The language about drug use is complex. The latest version of the manual that defines diseases and disorders (DSM-V) no longer refers to “dependence” and uses “addiction” instead. In this handbook, we continue to use “dependence” to refer to our experience of “needing the drug” and significant withdrawal symptoms when trying to quit or cut down on our use. Deciding to seek help is an important step in any process of recovery. You are making a wise decision to seek help now. People dependent on opioid drugs and not receiving opioid substitution treatment (OST) are many times more likely to die or be seriously harmed by problem drug use.


Keywords: HIV/AIDS, OST, testing, harm reduction, stigma

 

Download Publication

Strategic Framework for Prevention of Parent to Child Transmission (PPTCT) of HIV in Pakistan. Khan A. (2017)

immage

This strategic framework provides a road map to scale-up PPTCT services in the most efficient manner, where value for money is achieved with the promise that no infected mother will be missed and no child will be born with HIV, where every HIV exposed infant will receive the much needed HIV test at 6 weeks of age, and linked to treatment where required.

 


Keywords: HIV, PPTCT, ART, treatment, care

 

Download Publication

Regional Action Plan for Viral Hepatitis in South-East Asia, 2016–2021. WHO, Regional Office for South-East Asia. (2017)

immage

Viral hepatitis now ranks as the seventh leading cause of mortality worldwide. Although mortality due to communicable diseases has declined globally, the absolute burden and relative ranking of viral hepatitis as a cause of mortality has increased between 1990 and 2013.

 

Viral hepatitis causes at least as many, if not more, deaths annually compared with TB, AIDS, or malaria. Mortality due to viral hepatitis is increasing with time, while that due to TB, HIV and malaria is declining. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections account for more than 90% of viral hepatitis-related deaths and disability, with hepatitis A and E being responsible for the remaining.

 


Keywords: HIV, TB, hepatitis, viral, prevention and control, public health, vaccination

 

Download Publication

Global Priority List of Antibiotic-resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. WHO. (2017)

immage

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. Previous PPLs, issued by the Centers for Disease Control and Prevention.


Keywords: new antibiotics, treatment, drugs, antibiotic resistance

 

Download Publication

Pages

database
Highlighted publications
http://aidsdatahub.org/sites/default/files/highlight-reference/document/DataHub_TB-HIV_Fact_Sheet_2018.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Monitoring_2018.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NSACP_Sri_Lanka_National_HIV_Communication_Strategy_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Status_of_National_AIDS_Response_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V1_North-East_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V2_West_South_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_State_Epi_factsheets_V3_Northern_Central_Eastern_region_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/NACO_Annual_report_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Cambodia_Estimations_and_projections_of_HIV_AIDS_at_Sub-national_level_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_HIV_drug_resistance_report_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_on_public_health_response_to_pretreatment_HIV_drug_resistance_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Guidelines_for_Managing_Advanced_HIV_Disease_and_Rapid_Initiation_of_ART_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_What_New_in_Treatment_Monitoring_Viral_Load_and_CD4_Testing_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_IBBS_2016-17.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Pakistan_Mapping_Key_Populations_2015-16.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_Global_AIDS_Update_2017_Data_2017_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Myanmar_National_Strategic_Plan_on_HIV_and_AIDS_2016-2020.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_2017_Global_AIDS_Monitoring_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Nepal-IBBS-FIDU-Kathmandu-valley-RI-2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_methods_for_deriving_estimates_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/2015_Size_Estimation_of_Key_Affected_Populations_in_Philippines.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Assessment_of_Decentralization_of_ART_in_MMR_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS-2016-prevention-gap-report_en.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Implementing_comprehensive_HIV_and_STI_programmes_with_transgender_people_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/UNAIDS_cities_ending_the_aids_epidemic_2016.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/Philippines_2015_IHBSS_Fact_Sheets_Nov2017.pdf
http://aidsdatahub.org/sites/default/files/highlight-reference/document/WHO_Consolidated_on_the_use_of_antiretroviral_drugs_for_treating_and_preventing_HIV_infection_2016.pdf
Calendar of events
Jul
11
(11 Jul - 11 Jul)
Jul
28
(28 Jul - 28 Jul)